Dare Bioscience Inc (DARE)

$2.11 +0.02 (0.96%)
Market Cap 28.17M
Revenue (ttm) 10,000.00
Net Income (ttm) -4.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -40,500.00%
Debt to Equity Ratio 0.00
Volume 81,700
Avg Vol 161,246
Day's Range N/A - N/A
Shares Out 13.48M
Stochastic %K 37%
Beta 1.14
Analysts Strong Sell
Price Target $10.75

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
Courtrightt
Courtrightt Oct. 24 at 10:44 PM
$DARE lol, been gone for a 2 or 3 years, anyone see rayray around? 😂
0 · Reply
Djdanny
Djdanny Oct. 24 at 5:53 PM
$DARE Tik tok tik tok .Still frozen
0 · Reply
Ceri78
Ceri78 Oct. 24 at 12:07 PM
$DARE any good fuc***g news today?
0 · Reply
Hudafin
Hudafin Oct. 23 at 9:27 PM
$DARE this stock is trash. Always has been.
0 · Reply
Ceri78
Ceri78 Oct. 23 at 5:36 PM
$DARE under 2 soon
0 · Reply
HMIC
HMIC Oct. 23 at 1:10 PM
$DARE
0 · Reply
Ceri78
Ceri78 Oct. 22 at 9:12 PM
$DARE this is a walking dead
0 · Reply
Ceri78
Ceri78 Oct. 21 at 6:27 PM
$DARE what? Don’t rise to much…🤣
0 · Reply
BlazerD
BlazerD Oct. 21 at 2:28 PM
$DARE does this stock always suck?
1 · Reply
alcheholicTrading
alcheholicTrading Oct. 17 at 12:23 AM
$DARE
0 · Reply
Latest News on DARE
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Sep 24, 2025, 8:00 AM EDT - 4 weeks ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:48 PM EDT - 2 months ago

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 2 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 29, 2025, 8:00 AM EDT - 3 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 3 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 1:09 PM EDT - 3 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 14, 2025, 8:00 AM EDT - 3 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 3 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 4 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:13 PM EDT - 5 months ago

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 5 months ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:14 PM EDT - 7 months ago

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 7 months ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 7 months ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 9 months ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 10 months ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:03 PM EST - 1 year ago

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:40 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:30 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 2, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:47 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 31, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 26, 2024, 4:30 PM EST - 1 year ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Jan 4, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 26, 2023, 8:00 AM EST - 1 year ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Dec 13, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:56 PM EST - 2 years ago

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 9, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Daré Bioscience to Participate in Three November Conferences

Nov 6, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience to Participate in Three November Conferences

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Courtrightt
Courtrightt Oct. 24 at 10:44 PM
$DARE lol, been gone for a 2 or 3 years, anyone see rayray around? 😂
0 · Reply
Djdanny
Djdanny Oct. 24 at 5:53 PM
$DARE Tik tok tik tok .Still frozen
0 · Reply
Ceri78
Ceri78 Oct. 24 at 12:07 PM
$DARE any good fuc***g news today?
0 · Reply
Hudafin
Hudafin Oct. 23 at 9:27 PM
$DARE this stock is trash. Always has been.
0 · Reply
Ceri78
Ceri78 Oct. 23 at 5:36 PM
$DARE under 2 soon
0 · Reply
HMIC
HMIC Oct. 23 at 1:10 PM
$DARE
0 · Reply
Ceri78
Ceri78 Oct. 22 at 9:12 PM
$DARE this is a walking dead
0 · Reply
Ceri78
Ceri78 Oct. 21 at 6:27 PM
$DARE what? Don’t rise to much…🤣
0 · Reply
BlazerD
BlazerD Oct. 21 at 2:28 PM
$DARE does this stock always suck?
1 · Reply
alcheholicTrading
alcheholicTrading Oct. 17 at 12:23 AM
$DARE
0 · Reply
sulljd74
sulljd74 Oct. 16 at 11:53 PM
$DARE some day some real news will hit........
0 · Reply
frankyboyz
frankyboyz Oct. 16 at 8:17 PM
With $IVF reversing nicely after FEMY went from 0.75 to 1.20 ill keep $CDT and $DARE on high watch
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Oct. 16 at 7:34 PM
$DARE Why pump without news? Maybe someone wants to sell volume because the price immediately fell back?
0 · Reply
BiotechJedi1728
BiotechJedi1728 Oct. 16 at 6:23 PM
$DARE Nice. Not in here as much but still have remaining position of few hundred shares at 2.10. Pump on IVF when real money is still Ovaprene and Sildenafil. Waiting on further announcements for those and shoots back over $10 again. In the meantime, Sabrina was a finalist for Women in Innovation as well. Good news stacking til the end of the quarter. So much nicer here with less haters now. https://www.linkedin.com/posts/dare-bioscience_we-are-thrilled-to-announce-that-our-president-activity-7384253773248069635-fGqV?utm_medium=ios_app&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M&utm_source=social_share_send&utm_campaign=copy_link
1 · Reply
OhLawdy
OhLawdy Oct. 16 at 5:46 PM
$DARE
0 · Reply
ahTony
ahTony Oct. 16 at 5:27 PM
$NIVF $IVF $DARE $FEMY
0 · Reply
stick_to_stocks
stick_to_stocks Oct. 16 at 5:11 PM
$DARE added again . Last pump I had just 400$ 😑
0 · Reply
TA_Kongen
TA_Kongen Oct. 16 at 5:10 PM
$NIVF $IVF $DARE $FEMY I.V.F. Accessibility plays. White House Set To Announce Proposal Seeking To Make I.V.F. More Accessible' - Source
1 · Reply
KingsOnly
KingsOnly Oct. 16 at 4:59 PM
$DARE spike
0 · Reply
zhusjason1
zhusjason1 Oct. 15 at 6:52 PM
$DARE funny no volume at all, no one buys or sells
1 · Reply
HodlQueen22
HodlQueen22 Oct. 8 at 9:34 PM
$DARE we finally starting to move up! Time to buy.. predicting news in the next several months or sooner.
0 · Reply
Djdanny
Djdanny Oct. 6 at 4:58 PM
$DARE
0 · Reply